

270.2

270.3

270.4

270.5

270.6

270.7

270.8

270.9

270.10

270.11

270.12

270.13

270.14

270.15

270.16

270.17

270.18

270.19

270.20

270.21

270.22

270.23

270.24

270.25

270.26

270.27

270.28

271.1

271.2

ARTICLE 8

SCHEDULING OF MARIJUANA

Section 1. Minnesota Statutes 2022, section 152.02, subdivision 2, is amended to read:

Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this subdivision.

(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following substances, including their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers, and salts is possible:

(1) acetylmethadol;

(2) allylprodine;

(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl acetate);

(4) alphameprodine;

(5) alphamethadol;

(6) alpha-methylfentanyl benzethidine;

(7) betacetylmethadol;

(8) betameprodine;

(9) betamethadol;

(10) betaprodine;

(11) clonitazene;

(12) dextromoramide;

(13) diampromide;

(14) diethylambutene;

(15) difenoxin;

(16) dimenoxadol;

(17) dimepheptanol;

(18) dimethylambutene;

(19) dioxaphetyl butyrate;

(20) dipipanone;

269.22

269.23

269.24

269.25

269.26

269.27

269.28

269.29

269.30

270.1

270.2

270.3

270.4

270.5

270.6

270.7

270.8

270.9

270.10

270.11

270.12

270.13

270.14

270.15

270.16

270.17

270.18

270.19

270.20

ARTICLE 8

SCHEDULING OF MARIJUANA

Section 1. Minnesota Statutes 2022, section 152.02, subdivision 2, is amended to read:

Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this subdivision.

(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following substances, including their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers, and salts is possible:

(1) acetylmethadol;

(2) allylprodine;

(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl acetate);

(4) alphameprodine;

(5) alphamethadol;

(6) alpha-methylfentanyl benzethidine;

(7) betacetylmethadol;

(8) betameprodine;

(9) betamethadol;

(10) betaprodine;

(11) clonitazene;

(12) dextromoramide;

(13) diampromide;

(14) diethylambutene;

(15) difenoxin;

(16) dimenoxadol;

(17) dimepheptanol;

(18) dimethylambutene;

(19) dioxaphetyl butyrate;

(20) dipipanone;

- 271.3 (21) ethylmethylthiambutene;
- 271.4 (22) etonitazene;
- 271.5 (23) etoxeridine;
- 271.6 (24) furethidine;
- 271.7 (25) hydroxypethidine;
- 271.8 (26) ketobemidone;
- 271.9 (27) levomoramide;
- 271.10 (28) levophenacylmorphane;
- 271.11 (29) 3-methylfentanyl;
- 271.12 (30) acetyl-alpha-methylfentanyl;
- 271.13 (31) alpha-methylthiofentanyl;
- 271.14 (32) benzylfentanyl beta-hydroxyfentanyl;
- 271.15 (33) beta-hydroxy-3-methylfentanyl;
- 271.16 (34) 3-methylthiofentanyl;
- 271.17 (35) thenylfentanyl;
- 271.18 (36) thiofentanyl;
- 271.19 (37) para-fluorofentanyl;
- 271.20 (38) morpheridine;
- 271.21 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
- 271.22 (40) noracymethadol;
- 271.23 (41) norlevorphanol;
- 271.24 (42) normethadone;
- 271.25 (43) norpipanone;
- 271.26 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
- 271.27 (45) phenadoxone;
- 272.1 (46) phenampromide;
- 272.2 (47) phenomorphan;
- 272.3 (48) phenoperidine;

- 270.21 (21) ethylmethylthiambutene;
- 270.22 (22) etonitazene;
- 270.23 (23) etoxeridine;
- 270.24 (24) furethidine;
- 270.25 (25) hydroxypethidine;
- 270.26 (26) ketobemidone;
- 270.27 (27) levomoramide;
- 271.1 (28) levophenacylmorphane;
- 271.2 (29) 3-methylfentanyl;
- 271.3 (30) acetyl-alpha-methylfentanyl;
- 271.4 (31) alpha-methylthiofentanyl;
- 271.5 (32) benzylfentanyl beta-hydroxyfentanyl;
- 271.6 (33) beta-hydroxy-3-methylfentanyl;
- 271.7 (34) 3-methylthiofentanyl;
- 271.8 (35) thenylfentanyl;
- 271.9 (36) thiofentanyl;
- 271.10 (37) para-fluorofentanyl;
- 271.11 (38) morpheridine;
- 271.12 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
- 271.13 (40) noracymethadol;
- 271.14 (41) norlevorphanol;
- 271.15 (42) normethadone;
- 271.16 (43) norpipanone;
- 271.17 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
- 271.18 (45) phenadoxone;
- 271.19 (46) phenampromide;
- 271.20 (47) phenomorphan;
- 271.21 (48) phenoperidine;

House Language H0100-11		CANNABIS-ARTICLE 8	May 03, 2023 01:01 PM	Senate Language UEH0100-2	
272.4	(49) piritramide;			271.22	(49) piritramide;
272.5	(50) proheptazine;			271.23	(50) proheptazine;
272.6	(51) properidine;			271.24	(51) properidine;
272.7	(52) propiram;			271.25	(52) propiram;
272.8	(53) racemoramide;			271.26	(53) racemoramide;
272.9	(54) tilidine;			271.27	(54) tilidine;
272.10	(55) trimeperidine;			272.1	(55) trimeperidine;
272.11	(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);			272.2	(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
272.12	(57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-			272.3	(57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
272.13	methylbenzamide(U47700);			272.4	methylbenzamide(U47700);
272.14	(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);			272.5	(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);
272.15	(59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol);			272.6	(59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol);
272.16	(60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropyl			272.7	(60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropyl
272.17	fentanyl);			272.8	fentanyl);
272.18	(61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) (butyryl fentanyl);			272.9	(61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) (butyryl fentanyl);
272.19	(62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) (MT-45);			272.10	(62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) (MT-45);
272.20	(63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl			272.11	(63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl
272.21	fentanyl);			272.12	fentanyl);
272.22	(64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);			272.13	(64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
272.23	(65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl);			272.14	(65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl);
272.24	(66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide			272.15	(66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide
272.25	(para-chloroisobutyryl fentanyl);			272.16	(para-chloroisobutyryl fentanyl);
272.26	(67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl			272.17	(67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl
272.27	fentanyl);			272.18	fentanyl);
272.28	(68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide			272.19	(68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide
272.29	(para-methoxybutyryl fentanyl);			272.20	(para-methoxybutyryl fentanyl);
273.1	(69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil);			272.21	(69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil);
273.2	(70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl			272.22	(70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl
273.3	fentanyl or para-fluoroisobutyryl fentanyl);			272.23	fentanyl or para-fluoroisobutyryl fentanyl);
273.4	(71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or			272.24	(71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or
273.5	acryloylfentanyl);			272.25	acryloylfentanyl);

273.6 (72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl
273.7 fentanyl);

273.8 (73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl
273.9 or 2-fluorofentanyl);

273.10 (74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide
273.11 (tetrahydrofuranyl fentanyl); and

273.12 (75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers,
273.13 esters and ethers, meaning any substance not otherwise listed under another federal
273.14 Administration Controlled Substance Code Number or not otherwise listed in this section,
273.15 and for which no exemption or approval is in effect under section 505 of the Federal Food,
273.16 Drug, and Cosmetic Act, United States Code , title 21, section 355, that is structurally related
273.17 to fentanyl by one or more of the following modifications:

273.18 (i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether
273.19 or not further substituted in or on the monocycle;

273.20 (ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo,
273.21 haloalkyl, amino, or nitro groups;

273.22 (iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether,
273.23 hydroxyl, halo, haloalkyl, amino, or nitro groups;

273.24 (iv) replacement of the aniline ring with any aromatic monocycle whether or not further
273.25 substituted in or on the aromatic monocycle; or

273.26 (v) replacement of the N-propionyl group by another acyl group.

273.27 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
273.28 and salts of isomers, unless specifically excepted or unless listed in another schedule,
273.29 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

273.30 (1) acetorphine;

273.31 (2) acetyldihydrocodeine;

274.1 (3) benzylmorphine;

274.2 (4) codeine methylbromide;

274.3 (5) codeine-n-oxide;

274.4 (6) cyprenorphine;

274.5 (7) desomorphine;

274.6 (8) dihydromorphine;

274.7 (9) drotebanol;

272.26 (72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl
272.27 fentanyl);

272.28 (73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl
272.29 or 2-fluorofentanyl);

273.1 (74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide
273.2 (tetrahydrofuranyl fentanyl); and

273.3 (75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers,
273.4 esters and ethers, meaning any substance not otherwise listed under another federal
273.5 Administration Controlled Substance Code Number or not otherwise listed in this section,
273.6 and for which no exemption or approval is in effect under section 505 of the Federal Food,
273.7 Drug, and Cosmetic Act, United States Code , title 21, section 355, that is structurally related
273.8 to fentanyl by one or more of the following modifications:

273.9 (i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether
273.10 or not further substituted in or on the monocycle;

273.11 (ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo,
273.12 haloalkyl, amino, or nitro groups;

273.13 (iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether,
273.14 hydroxyl, halo, haloalkyl, amino, or nitro groups;

273.15 (iv) replacement of the aniline ring with any aromatic monocycle whether or not further
273.16 substituted in or on the aromatic monocycle; or

273.17 (v) replacement of the N-propionyl group by another acyl group.

273.18 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
273.19 and salts of isomers, unless specifically excepted or unless listed in another schedule,
273.20 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

273.21 (1) acetorphine;

273.22 (2) acetyldihydrocodeine;

273.23 (3) benzylmorphine;

273.24 (4) codeine methylbromide;

273.25 (5) codeine-n-oxide;

273.26 (6) cyprenorphine;

273.27 (7) desomorphine;

273.28 (8) dihydromorphine;

273.29 (9) drotebanol;

274.8	(10) etorphine;	273.30	(10) etorphine;
274.9	(11) heroin;	274.1	(11) heroin;
274.10	(12) hydromorphenol;	274.2	(12) hydromorphenol;
274.11	(13) methylodesorphine;	274.3	(13) methylodesorphine;
274.12	(14) methylidihydromorphine;	274.4	(14) methylidihydromorphine;
274.13	(15) morphine methylbromide;	274.5	(15) morphine methylbromide;
274.14	(16) morphine methylsulfonate;	274.6	(16) morphine methylsulfonate;
274.15	(17) morphine-n-oxide;	274.7	(17) morphine-n-oxide;
274.16	(18) myrophine;	274.8	(18) myrophine;
274.17	(19) nicocodeine;	274.9	(19) nicocodeine;
274.18	(20) nicomorphine;	274.10	(20) nicomorphine;
274.19	(21) normorphine;	274.11	(21) normorphine;
274.20	(22) pholcodine; and	274.12	(22) pholcodine; and
274.21	(23) thebacon.	274.13	(23) thebacon.
274.22	(d) Hallucinogens. Any material, compound, mixture or preparation which contains any	274.14	(d) Hallucinogens. Any material, compound, mixture or preparation which contains any
274.23	quantity of the following substances, their analogs, salts, isomers (whether optical, positional,	274.15	quantity of the following substances, their analogs, salts, isomers (whether optical, positional,
274.24	or geometric), and salts of isomers, unless specifically excepted or unless listed in another	274.16	or geometric), and salts of isomers, unless specifically excepted or unless listed in another
274.25	schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is	274.17	schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is
274.26	possible:	274.18	possible:
274.27	(1) methylenedioxy amphetamine;	274.19	(1) methylenedioxy amphetamine;
274.28	(2) methylenedioxymethamphetamine;	274.20	(2) methylenedioxymethamphetamine;
275.1	(3) methylenedioxy-N-ethylamphetamine (MDEA);	274.21	(3) methylenedioxy-N-ethylamphetamine (MDEA);
275.2	(4) n-hydroxy-methylenedioxyamphetamine;	274.22	(4) n-hydroxy-methylenedioxyamphetamine;
275.3	(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);	274.23	(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
275.4	(6) 2,5-dimethoxyamphetamine (2,5-DMA);	274.24	(6) 2,5-dimethoxyamphetamine (2,5-DMA);
275.5	(7) 4-methoxyamphetamine;	274.25	(7) 4-methoxyamphetamine;
275.6	(8) 5-methoxy-3, 4-methylenedioxyamphetamine;	274.26	(8) 5-methoxy-3, 4-methylenedioxyamphetamine;
275.7	(9) alpha-ethyltryptamine;	274.27	(9) alpha-ethyltryptamine;
275.8	(10) bufotenine;	274.28	(10) bufotenine;

House Language H0100-11		CANNABIS-ARTICLE 8	May 03, 2023 01:01 PM	Senate Language UEH0100-2	
275.9	(11) diethyltryptamine;			275.1	(11) diethyltryptamine;
275.10	(12) dimethyltryptamine;			275.2	(12) dimethyltryptamine;
275.11	(13) 3,4,5-trimethoxyamphetamine;			275.3	(13) 3,4,5-trimethoxyamphetamine;
275.12	(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);			275.4	(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
275.13	(15) ibogaine;			275.5	(15) ibogaine;
275.14	(16) lysergic acid diethylamide (LSD);			275.6	(16) lysergic acid diethylamide (LSD);
275.15	(17) mescaline;			275.7	(17) mescaline;
275.16	(18) parahexyl;			275.8	(18) parahexyl;
275.17	(19) N-ethyl-3-piperidyl benzilate;			275.9	(19) N-ethyl-3-piperidyl benzilate;
275.18	(20) N-methyl-3-piperidyl benzilate;			275.10	(20) N-methyl-3-piperidyl benzilate;
275.19	(21) psilocybin;			275.11	(21) psilocybin;
275.20	(22) psilocyn;			275.12	(22) psilocyn;
275.21	(23) tenocyclidine (TCP or TCP);			275.13	(23) tenocyclidine (TCP or TCP);
275.22	(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);			275.14	(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
275.23	(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);			275.15	(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
275.24	(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);			275.16	(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
275.25	(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);			275.17	(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
275.26	(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);			275.18	(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
275.27	(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);			275.19	(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
276.1	(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);			275.20	(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
276.2	(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);			275.21	(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
276.3	(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);			275.22	(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
276.4	(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);			275.23	(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
276.5	(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);			275.24	(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
276.6	(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);			275.25	(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
276.7	(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);			275.26	(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
276.8	(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);			275.27	(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);

276.9	(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine	276.1	(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
276.10	(2-CB-FLY);	276.2	(2-CB-FLY);
276.11	(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);	276.3	(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
276.12	(40) alpha-methyltryptamine (AMT);	276.4	(40) alpha-methyltryptamine (AMT);
276.13	(41) N,N-diisopropyltryptamine (DiPT);	276.5	(41) N,N-diisopropyltryptamine (DiPT);
276.14	(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);	276.6	(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
276.15	(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);	276.7	(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
276.16	(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);	276.8	(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
276.17	(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);	276.9	(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
276.18	(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);	276.10	(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
276.19	(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);	276.11	(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
276.20	(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);	276.12	(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
276.21	(49) 5-methoxy- α -methyltryptamine (5-MeO-AMT);	276.13	(49) 5-methoxy- α -methyltryptamine (5-MeO-AMT);
276.22	(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);	276.14	(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
276.23	(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);	276.15	(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
276.24	(52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);	276.16	(52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
276.25	(53) 5-methoxy- α -ethyltryptamine (5-MeO-AET);	276.17	(53) 5-methoxy- α -ethyltryptamine (5-MeO-AET);
276.26	(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);	276.18	(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
276.27	(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);	276.19	(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
277.1	(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);	276.20	(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
277.2	(57) methoxetamine (MXE);	276.21	(57) methoxetamine (MXE);
277.3	(58) 5-iodo-2-aminoindane (5-IAI);	276.22	(58) 5-iodo-2-aminoindane (5-IAI);
277.4	(59) 5,6-methylenedioxy-2-aminoindane (MDAI);	276.23	(59) 5,6-methylenedioxy-2-aminoindane (MDAI);
277.5	(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);	276.24	(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
277.6	(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);	276.25	(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
277.7	(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);	276.26	(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
277.8	(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);	276.27	(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
277.9	(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);	277.1	(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);

House Language H0100-11		CANNABIS-ARTICLE 8		May 03, 2023 01:01 PM		Senate Language UEH0100-2	
277.10	(65) N,N-Dipropyltryptamine (DPT);	277.10	(65) N,N-Dipropyltryptamine (DPT);	277.2	(65) N,N-Dipropyltryptamine (DPT);	277.2	(65) N,N-Dipropyltryptamine (DPT);
277.11	(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);	277.11	(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);	277.3	(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);	277.3	(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
277.12	(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);	277.12	(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);	277.4	(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);	277.4	(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
277.13	(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);	277.13	(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);	277.5	(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);	277.5	(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
277.14	(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);	277.14	(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);	277.6	(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);	277.6	(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
277.15	(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine,	277.15	(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine,	277.7	(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine,	277.7	(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine,
277.16	ethketamine, NENK);	277.16	ethketamine, NENK);	277.8	ethketamine, NENK);	277.8	ethketamine, NENK);
277.17	(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);	277.17	(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);	277.9	(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);	277.9	(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
277.18	(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and	277.18	(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and	277.10	(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and	277.10	(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
277.19	(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).	277.19	(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).	277.11	(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).	277.11	(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
277.20	(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii	277.12	(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii	277.12	(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii	277.12	(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii
277.21	Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,	277.13	Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,	277.13	Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,	277.13	Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,
277.22	and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,	277.14	and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,	277.14	and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,	277.14	and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,
277.23	its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not	277.15	its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not	277.15	its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not	277.15	its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not
277.24	apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian	277.16	apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian	277.16	apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian	277.16	apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian
277.25	Church, and members of the American Indian Church are exempt from registration. Any	277.17	Church, and members of the American Indian Church are exempt from registration. Any	277.17	Church, and members of the American Indian Church are exempt from registration. Any	277.17	Church, and members of the American Indian Church are exempt from registration. Any
277.26	person who manufactures peyote for or distributes peyote to the American Indian Church,	277.18	person who manufactures peyote for or distributes peyote to the American Indian Church,	277.18	person who manufactures peyote for or distributes peyote to the American Indian Church,	277.18	person who manufactures peyote for or distributes peyote to the American Indian Church,
277.27	however, is required to obtain federal registration annually and to comply with all other	277.19	however, is required to obtain federal registration annually and to comply with all other	277.19	however, is required to obtain federal registration annually and to comply with all other	277.19	however, is required to obtain federal registration annually and to comply with all other
277.28	requirements of law.	277.20	requirements of law.	277.20	requirements of law.	277.20	requirements of law.
277.29	(f) Central nervous system depressants. Unless specifically excepted or unless listed in	277.21	(f) Central nervous system depressants. Unless specifically excepted or unless listed in	277.21	(f) Central nervous system depressants. Unless specifically excepted or unless listed in	277.21	(f) Central nervous system depressants. Unless specifically excepted or unless listed in
277.30	another schedule, any material compound, mixture, or preparation which contains any	277.22	another schedule, any material compound, mixture, or preparation which contains any	277.22	another schedule, any material compound, mixture, or preparation which contains any	277.22	another schedule, any material compound, mixture, or preparation which contains any
278.1	quantity of the following substances, their analogs, salts, isomers, and salts of isomers	277.23	quantity of the following substances, their analogs, salts, isomers, and salts of isomers	277.23	quantity of the following substances, their analogs, salts, isomers, and salts of isomers	277.23	quantity of the following substances, their analogs, salts, isomers, and salts of isomers
278.2	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:	277.24	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:	277.24	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:	277.24	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
278.3	(1) mecloqualone;	277.25	(1) mecloqualone;	277.25	(1) mecloqualone;	277.25	(1) mecloqualone;
278.4	(2) methaqualone;	277.26	(2) methaqualone;	277.26	(2) methaqualone;	277.26	(2) methaqualone;
278.5	(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;	277.27	(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;	277.27	(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;	277.27	(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
278.6	(4) flunitrazepam;	277.28	(4) flunitrazepam;	277.28	(4) flunitrazepam;	277.28	(4) flunitrazepam;
278.7	(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,	277.29	(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,	277.29	(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,	277.29	(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,
278.8	methoxyketamine);	277.30	methoxyketamine);	277.30	methoxyketamine);	277.30	methoxyketamine);
278.9	(6) tianeptine;	278.1	(6) tianeptine;	278.1	(6) tianeptine;	278.1	(6) tianeptine;
278.10	(7) clonazepam;	278.2	(7) clonazepam;	278.2	(7) clonazepam;	278.2	(7) clonazepam;
278.11	(8) etizolam;	278.3	(8) etizolam;	278.3	(8) etizolam;	278.3	(8) etizolam;

House Language H0100-11		CANNABIS-ARTICLE 8		May 03, 2023 01:01 PM		Senate Language UEH0100-2	
278.12	(9) flubromazolam; and	278.4	(9) flubromazolam; and	278.4	(9) flubromazolam; and	278.4	(9) flubromazolam; and
278.13	(10) flubromazepam.	278.5	(10) flubromazepam.	278.5	(10) flubromazepam.	278.5	(10) flubromazepam.
278.14	(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any	278.6	(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any	278.6	(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any	278.6	(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any
278.15	material compound, mixture, or preparation which contains any quantity of the following	278.7	material compound, mixture, or preparation which contains any quantity of the following	278.7	material compound, mixture, or preparation which contains any quantity of the following	278.7	material compound, mixture, or preparation which contains any quantity of the following
278.16	substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the	278.8	substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the	278.8	substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the	278.8	substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the
278.17	analogs, salts, isomers, and salts of isomers is possible:	278.9	analogs, salts, isomers, and salts of isomers is possible:	278.9	analogs, salts, isomers, and salts of isomers is possible:	278.9	analogs, salts, isomers, and salts of isomers is possible:
278.18	(1) aminorex;	278.10	(1) aminorex;	278.10	(1) aminorex;	278.10	(1) aminorex;
278.19	(2) cathinone;	278.11	(2) cathinone;	278.11	(2) cathinone;	278.11	(2) cathinone;
278.20	(3) fenethylline;	278.12	(3) fenethylline;	278.12	(3) fenethylline;	278.12	(3) fenethylline;
278.21	(4) methcathinone;	278.13	(4) methcathinone;	278.13	(4) methcathinone;	278.13	(4) methcathinone;
278.22	(5) methylaminorex;	278.14	(5) methylaminorex;	278.14	(5) methylaminorex;	278.14	(5) methylaminorex;
278.23	(6) N,N-dimethylamphetamine;	278.15	(6) N,N-dimethylamphetamine;	278.15	(6) N,N-dimethylamphetamine;	278.15	(6) N,N-dimethylamphetamine;
278.24	(7) N-benzylpiperazine (BZP);	278.16	(7) N-benzylpiperazine (BZP);	278.16	(7) N-benzylpiperazine (BZP);	278.16	(7) N-benzylpiperazine (BZP);
278.25	(8) methylmethcathinone (mephedrone);	278.17	(8) methylmethcathinone (mephedrone);	278.17	(8) methylmethcathinone (mephedrone);	278.17	(8) methylmethcathinone (mephedrone);
278.26	(9) 3,4-methylenedioxy-N-methylcathinone (methydone);	278.18	(9) 3,4-methylenedioxy-N-methylcathinone (methydone);	278.18	(9) 3,4-methylenedioxy-N-methylcathinone (methydone);	278.18	(9) 3,4-methylenedioxy-N-methylcathinone (methydone);
278.27	(10) methoxymethcathinone (methedrone);	278.19	(10) methoxymethcathinone (methedrone);	278.19	(10) methoxymethcathinone (methedrone);	278.19	(10) methoxymethcathinone (methedrone);
278.28	(11) methylenedioxypropylvalerone (MDPV);	278.20	(11) methylenedioxypropylvalerone (MDPV);	278.20	(11) methylenedioxypropylvalerone (MDPV);	278.20	(11) methylenedioxypropylvalerone (MDPV);
279.1	(12) 3-fluoro-N-methylcathinone (3-FMC);	278.21	(12) 3-fluoro-N-methylcathinone (3-FMC);	278.21	(12) 3-fluoro-N-methylcathinone (3-FMC);	278.21	(12) 3-fluoro-N-methylcathinone (3-FMC);
279.2	(13) methylethcathinone (MEC);	278.22	(13) methylethcathinone (MEC);	278.22	(13) methylethcathinone (MEC);	278.22	(13) methylethcathinone (MEC);
279.3	(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);	278.23	(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);	278.23	(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);	278.23	(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
279.4	(15) dimethylmethcathinone (DMMC);	278.24	(15) dimethylmethcathinone (DMMC);	278.24	(15) dimethylmethcathinone (DMMC);	278.24	(15) dimethylmethcathinone (DMMC);
279.5	(16) fluoroamphetamine;	278.25	(16) fluoroamphetamine;	278.25	(16) fluoroamphetamine;	278.25	(16) fluoroamphetamine;
279.6	(17) fluoromethamphetamine;	278.26	(17) fluoromethamphetamine;	278.26	(17) fluoromethamphetamine;	278.26	(17) fluoromethamphetamine;
279.7	(18) α -methylaminobutyrophenone (MABP or buphedrone);	278.27	(18) α -methylaminobutyrophenone (MABP or buphedrone);	278.27	(18) α -methylaminobutyrophenone (MABP or buphedrone);	278.27	(18) α -methylaminobutyrophenone (MABP or buphedrone);
279.8	(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);	278.28	(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);	278.28	(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);	278.28	(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
279.9	(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);	279.1	(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);	279.1	(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);	279.1	(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
279.10	(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or	279.2	(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or	279.2	(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or	279.2	(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or
279.11	naphyrone);	279.3	naphyrone);	279.3	naphyrone);	279.3	naphyrone);
279.12	(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);	279.4	(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);	279.4	(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);	279.4	(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);

279.13 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
279.14 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
279.15 (25) 4-methyl-N-ethylcathinone (4-MEC);
279.16 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
279.17 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
279.18 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
279.19 (29) 4-fluoro-N-methylcathinone (4-FMC);
279.20 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
279.21 (31) alpha-pyrrolidinobutiophenone (α -PBP);
279.22 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
279.23 (33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
279.24 (34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
279.25 (35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
279.26 (36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
279.27 (37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
280.1 (38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP);
280.2 (39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentylone, ephylone);
280.3 and
280.4 (40) any other substance, except bupropion or compounds listed under a different
280.5 schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
280.6 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
280.7 compound is further modified in any of the following ways:

280.8 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
280.9 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
280.10 system by one or more other univalent substituents;

280.11 (ii) by substitution at the 3-position with an acyclic alkyl substituent;

280.12 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
280.13 methoxybenzyl groups; or

280.14 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.

280.15 ~~(h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically~~
280.16 ~~excepted or unless listed in another schedule, any natural or synthetic material, compound,~~

279.5 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
279.6 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
279.7 (25) 4-methyl-N-ethylcathinone (4-MEC);
279.8 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
279.9 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
279.10 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
279.11 (29) 4-fluoro-N-methylcathinone (4-FMC);
279.12 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
279.13 (31) alpha-pyrrolidinobutiophenone (α -PBP);
279.14 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
279.15 (33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
279.16 (34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
279.17 (35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
279.18 (36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
279.19 (37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
279.20 (38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP);
279.21 (39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentylone, ephylone);
279.22 and
279.23 (40) any other substance, except bupropion or compounds listed under a different
279.24 schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
279.25 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
279.26 compound is further modified in any of the following ways:

279.27 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
279.28 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
279.29 system by one or more other univalent substituents;

280.1 (ii) by substitution at the 3-position with an acyclic alkyl substituent;

280.2 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
280.3 methoxybenzyl groups; or

280.4 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.

280.5 ~~(h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically~~
280.6 ~~excepted or unless listed in another schedule, any natural or synthetic material, compound,~~

280.17 mixture, or preparation that contains any quantity of the following substances, their analogs,
280.18 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence
280.19 of the isomers, esters, ethers, or salts is possible:

280.20 (1) marijuana;

280.21 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except
280.22 that tetrahydrocannabinols do not include any material, compound, mixture, or preparation
280.23 that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; synthetic
280.24 equivalents of the substances contained in the cannabis plant or in the resinous extractives
280.25 of the plant; or synthetic substances with similar chemical structure and pharmacological
280.26 activity to those substances contained in the plant or resinous extract, including, but not
280.27 limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4
280.28 cis or trans tetrahydrocannabinol;

280.29 (3) (h) Synthetic cannabinoids, including the following substances:

280.30 (i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole
280.31 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
280.32 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
281.1 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
281.2 extent and whether or not substituted in the naphthyl ring to any extent. Examples of
281.3 naphthoylindoles include, but are not limited to:

281.4 (i) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);

281.5 (ii) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);

281.6 (iii) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);

281.7 (iv) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

281.8 (v) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);

281.9 (vi) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);

281.10 (vii) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

281.11 (viii) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);

281.12 (ix) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

281.13 (x) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).

281.14 (2) Naphthylmethylindoles, which are any compounds containing a
281.15 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the
281.16 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
281.17 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
281.18 substituted in the indole ring to any extent and whether or not substituted in the naphthyl
281.19 ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:

280.7 mixture, or preparation that contains any quantity of the following substances, their analogs,
280.8 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence
280.9 of the isomers, esters, ethers, or salts is possible:

280.10 (1) marijuana;

280.11 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except
280.12 that tetrahydrocannabinols do not include any material, compound, mixture, or preparation
280.13 that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; synthetic
280.14 equivalents of the substances contained in the cannabis plant or in the resinous extractives
280.15 of the plant; or synthetic substances with similar chemical structure and pharmacological
280.16 activity to those substances contained in the plant or resinous extract, including, but not
280.17 limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4
280.18 cis or trans tetrahydrocannabinol;

280.19 (3) (h) Synthetic Artificial cannabinoids, including the following substances:

280.20 (i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole
280.21 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
280.22 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
280.23 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
280.24 extent and whether or not substituted in the naphthyl ring to any extent. Examples of
280.25 naphthoylindoles include, but are not limited to:

280.26 (i) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);

280.27 (ii) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);

280.28 (iii) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);

280.29 (iv) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

280.30 (v) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);

280.31 (vi) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);

281.1 (vii) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

281.2 (viii) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);

281.3 (ix) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

281.4 (x) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).

281.5 (2) Naphthylmethylindoles, which are any compounds containing a
281.6 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the
281.7 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
281.8 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
281.9 substituted in the indole ring to any extent and whether or not substituted in the naphthyl
281.10 ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:

House Language H0100-11		CANNABIS-ARTICLE 8	May 03, 2023 01:01 PM	Senate Language UEH0100-2	
281.20	(A) <u>(i)</u>	1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);	281.11	(A) <u>(i)</u>	1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
281.21	(B) <u>(ii)</u>	1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).	281.12	(B) <u>(ii)</u>	1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
281.22	(iii) <u>(3)</u>	Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole	281.13	(iii) <u>(3)</u>	Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole
281.23		structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,	281.14		structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
281.24		alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or	281.15		alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
281.25		2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any	281.16		2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any
281.26		extent, whether or not substituted in the naphthyl ring to any extent. Examples of	281.17		extent, whether or not substituted in the naphthyl ring to any extent. Examples of
281.27		naphthoylpyrroles include, but are not limited to,	281.18		naphthoylpyrroles include, but are not limited to,
281.28		(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).	281.19		(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
281.29	(iv) <u>(4)</u>	Naphthylmethylindenes, which are any compounds containing a	281.20	(iv) <u>(4)</u>	Naphthylmethylindenes, which are any compounds containing a
281.30		naphthylideneindene structure with substitution at the 3-position of the indene ring by an	281.21		naphthylideneindene structure with substitution at the 3-position of the indene ring by an
281.31		alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,	281.22		alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
282.1		1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further	281.23		1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further
282.2		substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring	281.24		substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring
282.3		to any extent. Examples of naphthylemethylindenes include, but are not limited to,	281.25		to any extent. Examples of naphthylemethylindenes include, but are not limited to,
282.4		E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).	281.26		E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
282.5	(v) <u>(5)</u>	Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole	281.27	(v) <u>(5)</u>	Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
282.6		structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,	281.28		structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
282.7		alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or	281.29		alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
282.8		2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any	281.30		2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
282.9		extent, whether or not substituted in the phenyl ring to any extent. Examples of	281.31		extent, whether or not substituted in the phenyl ring to any extent. Examples of
282.10		phenylacetylindoles include, but are not limited to:	281.32		phenylacetylindoles include, but are not limited to:
282.11	(A) <u>(i)</u>	1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);	281.33	(A) <u>(i)</u>	1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
282.12	(B) <u>(ii)</u>	1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);	282.1	(B) <u>(ii)</u>	1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
282.13	(C) <u>(iii)</u>	1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);	282.2	(C) <u>(iii)</u>	1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
282.14	(D) <u>(iv)</u>	1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).	282.3	(D) <u>(iv)</u>	1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
282.15	(v) <u>(6)</u>	Cyclohexylphenols, which are compounds containing a	282.4	(v) <u>(6)</u>	Cyclohexylphenols, which are compounds containing a
282.16		2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic	282.5		2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic
282.17		ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,	282.6		ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
282.18		1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted	282.7		1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted
282.19		in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not	282.8		in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not
282.20		limited to:	282.9		limited to:
282.21	(A) <u>(i)</u>	5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);	282.10	(A) <u>(i)</u>	5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
282.22	(B) <u>(ii)</u>	5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol	282.11	(B) <u>(ii)</u>	5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
282.23		(Cannabicyclohexanol or CP 47,497 C8 homologue);	282.12		(Cannabicyclohexanol or CP 47,497 C8 homologue);

282.24 ~~(C)~~ (iii) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
282.25 -phenol (CP 55,940).

282.26 ~~(vii)~~ (7) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole
282.27 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
282.28 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or
282.29 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
282.30 extent and whether or not substituted in the phenyl ring to any extent. Examples of
282.31 benzoylindoles include, but are not limited to:

282.32 ~~(A)~~ (i) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);

283.1 ~~(B)~~ (ii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);

283.2 ~~(C)~~ (iii) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
283.3 (WIN 48,098 or Pravadoline).

283.4 ~~(viii)~~ (8) Others specifically named:

283.5 ~~(A)~~ (i) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
283.6 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);

283.7 ~~(B)~~ (ii) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
283.8 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);

283.9 ~~(C)~~ (iii) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
283.10 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);

283.11 ~~(D)~~ (iv) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);

283.12 ~~(E)~~ (v) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
283.13 (XLR-11);

283.14 ~~(F)~~ (vi) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
283.15 (AKB-48(APINACA));

283.16 ~~(G)~~ (vii) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
283.17 (5-Fluoro-AKB-48);

283.18 ~~(H)~~ (viii) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);

283.19 ~~(I)~~ (ix) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro
283.20 PB-22);

283.21 ~~(J)~~ (x) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide
283.22 (AB-PINACA);

283.23 ~~(K)~~ (xi) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
283.24 1H-indazole-3-carboxamide (AB-FUBINACA);

282.13 ~~(C)~~ (iii) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
282.14 -phenol (CP 55,940).

282.15 ~~(vii)~~ (7) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole
282.16 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
282.17 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or
282.18 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
282.19 extent and whether or not substituted in the phenyl ring to any extent. Examples of
282.20 benzoylindoles include, but are not limited to:

282.21 ~~(A)~~ (i) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);

282.22 ~~(B)~~ (ii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);

282.23 ~~(C)~~ (iii) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
282.24 (WIN 48,098 or Pravadoline).

282.25 ~~(viii)~~ (8) Others specifically named:

282.26 ~~(A)~~ (i) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
282.27 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);

282.28 ~~(B)~~ (ii) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
282.29 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);

282.30 ~~(C)~~ (iii) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
282.31 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);

283.1 ~~(D)~~ (iv) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);

283.2 ~~(E)~~ (v) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
283.3 (XLR-11);

283.4 ~~(F)~~ (vi) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
283.5 (AKB-48(APINACA));

283.6 ~~(G)~~ (vii) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
283.7 (5-Fluoro-AKB-48);

283.8 ~~(H)~~ (viii) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);

283.9 ~~(I)~~ (ix) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro
283.10 PB-22);

283.11 ~~(J)~~ (x) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide
283.12 (AB-PINACA);

283.13 ~~(K)~~ (xi) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
283.14 1H-indazole-3-carboxamide (AB-FUBINACA);

283.25 ~~(F)~~ (xii) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
283.26 indazole-3-carboxamide(AB-CHMINACA);

283.27 ~~(M)~~ (xiii) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-
283.28 methylbutanoate (5-fluoro-AMB);

283.29 ~~(N)~~ (xiv) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);

284.1 ~~(O)~~ (xv) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone)
284.2 (FUBIMINA);

284.3 ~~(P)~~ (xvi) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
284.4 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);

284.5 ~~(Q)~~ (xvii) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
284.6 -1H-indole-3-carboxamide (5-fluoro-ABICA);

284.7 ~~(R)~~ (xviii) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
284.8 -1H-indole-3-carboxamide;

284.9 ~~(S)~~ (xix) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
284.10 -1H-indazole-3-carboxamide;

284.11 ~~(T)~~ (xx) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)
284.12 -3,3-dimethylbutanoate;

284.13 ~~(U)~~ (xxi) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1
284.14 H-indazole-3-carboxamide (MAB-CHMINACA);

284.15 ~~(V)~~ (xxii)
284.16 N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
284.17 (ADB-PINACA);

284.18 ~~(W)~~ (xxiii) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);

284.19 ~~(X)~~ (xxiv)
284.20 N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
284.21 3-carboxamide. (APP-CHMINACA);

284.22 ~~(Y)~~ (xxv) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and

284.23 ~~(Z)~~ (xxvi) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate
284.24 (MMB-CHMICA).

284.25 ~~(aa)~~ (9) Additional substances specifically named:

284.26 ~~(A)~~ (i) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
284.27 H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);

284.28 ~~(B)~~ (ii) 1-(4-cyanobutyl)-N-(2- phenylpropan-2-yl)-1 H-indazole-3-carboxamide
284.29 (4-CN-Cumyl-Butinaca);

283.15 ~~(F)~~ (xii) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
283.16 indazole-3-carboxamide(AB-CHMINACA);

283.17 ~~(M)~~ (xiii) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-
283.18 methylbutanoate (5-fluoro-AMB);

283.19 ~~(N)~~ (xiv) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);

283.20 ~~(O)~~ (xv) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone)
283.21 (FUBIMINA);

283.22 ~~(P)~~ (xvi) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
283.23 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);

283.24 ~~(Q)~~ (xvii) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
283.25 -1H-indole-3-carboxamide (5-fluoro-ABICA);

283.26 ~~(R)~~ (xviii) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
283.27 -1H-indole-3-carboxamide;

283.28 ~~(S)~~ (xix) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
283.29 -1H-indazole-3-carboxamide;

283.30 ~~(T)~~ (xx) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)
283.31 -3,3-dimethylbutanoate;

284.1 ~~(U)~~ (xxi) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1
284.2 H-indazole-3-carboxamide (MAB-CHMINACA);

284.3 ~~(V)~~ (xxii)
284.4 N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
284.5 (ADB-PINACA);

284.6 ~~(W)~~ (xxiii) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);

284.7 ~~(X)~~ (xxiv)
284.8 N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
284.9 3-carboxamide. (APP-CHMINACA);

284.10 ~~(Y)~~ (xxv) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and

284.11 ~~(Z)~~ (xxvi) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate
284.12 (MMB-CHMICA).

284.13 ~~(aa)~~ (9) Additional substances specifically named:

284.14 ~~(A)~~ (i) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
284.15 H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);

284.16 ~~(B)~~ (ii) 1-(4-cyanobutyl)-N-(2- phenylpropan-2-yl)-1 H-indazole-3-carboxamide
284.17 (4-CN-Cumyl-Butinaca);

284.30 ~~(C)~~ (iii) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201;
284.31 CBL2201);

285.1 ~~(D)~~ (iv) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1
285.2 H-indazole-3-carboxamide (5F-ABPINACA);

285.3 ~~(F)~~ (v) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
285.4 (MDMB CHMICA);

285.5 ~~(F)~~ (vi) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
285.6 (5F-ADB; 5F-MDMB-PINACA); and

285.7 ~~(G)~~ (vii) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)
285.8 1H-indazole-3-carboxamide (ADB-FUBINACA).

285.9 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended
285.10 for human consumption.

285.11 **EFFECTIVE DATE.** This section is effective the day following final enactment.

285.12 Sec. 2. Minnesota Statutes 2022, section 152.02, subdivision 4, is amended to read:

285.13 Subd. 4. **Schedule III.** (a) Schedule III consists of the substances listed in this subdivision.

285.14 (b) Stimulants. Unless specifically excepted or unless listed in another schedule, any
285.15 material, compound, mixture, or preparation which contains any quantity of the following
285.16 substances having a potential for abuse associated with a stimulant effect on the central
285.17 nervous system, including its salts, isomers, and salts of such isomers whenever the existence
285.18 of such salts, isomers, and salts of isomers is possible within the specific chemical
285.19 designation:

285.20 (1) benzphetamine;

285.21 (2) chlorphentermine;

285.22 (3) clortermine;

285.23 (4) phendimetrazine.

285.24 (c) Depressants. Unless specifically excepted or unless listed in another schedule, any
285.25 material, compound, mixture, or preparation which contains any quantity of the following
285.26 substances having a potential for abuse associated with a depressant effect on the central
285.27 nervous system:

285.28 (1) any compound, mixture, or preparation containing amobarbital, secobarbital,
285.29 pentobarbital or any salt thereof and one or more other active medicinal ingredients which
285.30 are not listed in any schedule;

284.18 ~~(C)~~ (iii) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201;
284.19 CBL2201);

284.20 ~~(D)~~ (iv) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1
284.21 H-indazole-3-carboxamide (5F-ABPINACA);

284.22 ~~(F)~~ (v) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
284.23 (MDMB CHMICA);

284.24 ~~(F)~~ (vi) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
284.25 (5F-ADB; 5F-MDMB-PINACA); and

284.26 ~~(G)~~ (vii) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)
284.27 1H-indazole-3-carboxamide (ADB-FUBINACA).

284.28 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended
284.29 for human consumption.

284.30 **EFFECTIVE DATE.** This section is effective the day following final enactment.

285.1 Sec. 2. Minnesota Statutes 2022, section 152.02, subdivision 4, is amended to read:

285.2 Subd. 4. **Schedule III.** (a) Schedule III consists of the substances listed in this subdivision.

285.3 (b) Stimulants. Unless specifically excepted or unless listed in another schedule, any
285.4 material, compound, mixture, or preparation which contains any quantity of the following
285.5 substances having a potential for abuse associated with a stimulant effect on the central
285.6 nervous system, including its salts, isomers, and salts of such isomers whenever the existence
285.7 of such salts, isomers, and salts of isomers is possible within the specific chemical
285.8 designation:

285.9 (1) benzphetamine;

285.10 (2) chlorphentermine;

285.11 (3) clortermine;

285.12 (4) phendimetrazine.

285.13 (c) Depressants. Unless specifically excepted or unless listed in another schedule, any
285.14 material, compound, mixture, or preparation which contains any quantity of the following
285.15 substances having a potential for abuse associated with a depressant effect on the central
285.16 nervous system:

285.17 (1) any compound, mixture, or preparation containing amobarbital, secobarbital,
285.18 pentobarbital or any salt thereof and one or more other active medicinal ingredients which
285.19 are not listed in any schedule;

House Language H0100-11	CANNABIS-ARTICLE 8	May 03, 2023 01:01 PM	Senate Language UEH0100-2
<div>286.1</div> <div>286.2</div> <div>286.3</div>	<div>(2) any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or</div> <div>any salt of any of these drugs and approved by the food and drug administration for marketing</div> <div>only as a suppository;</div>	<div>285.20</div> <div>285.21</div> <div>285.22</div>	<div>(2) any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or</div> <div>any salt of any of these drugs and approved by the food and drug administration for marketing</div> <div>only as a suppository;</div>
<div>286.4</div> <div>286.5</div> <div>286.6</div>	<div>(3) any substance which contains any quantity of a derivative of barbituric acid, or any</div> <div>salt of a derivative of barbituric acid, except those substances which are specifically listed</div> <div>in other schedules;</div>	<div>285.23</div> <div>285.24</div> <div>285.25</div>	<div>(3) any substance which contains any quantity of a derivative of barbituric acid, or any</div> <div>salt of a derivative of barbituric acid, except those substances which are specifically listed</div> <div>in other schedules;</div>
<div>286.7</div> <div>286.8</div> <div>286.9</div>	<div>(4) any drug product containing gamma hydroxybutyric acid, including its salts, isomers,</div> <div>and salts of isomers, for which an application is approved under section 505 of the federal</div> <div>Food, Drug, and Cosmetic Act;</div>	<div>285.26</div> <div>285.27</div> <div>285.28</div>	<div>(4) any drug product containing gamma hydroxybutyric acid, including its salts, isomers,</div> <div>and salts of isomers, for which an application is approved under section 505 of the federal</div> <div>Food, Drug, and Cosmetic Act;</div>
<div>286.10</div>	<div>(5) any of the following substances:</div>	<div>285.29</div>	<div>(5) any of the following substances:</div>
<div>286.11</div>	<div>(i) chlorhexadol;</div>	<div>285.30</div>	<div>(i) chlorhexadol;</div>
<div>286.12</div>	<div>(ii) ketamine, its salts, isomers and salts of isomers;</div>	<div>285.31</div>	<div>(ii) ketamine, its salts, isomers and salts of isomers;</div>
<div>286.13</div>	<div>(iii) lysergic acid;</div>	<div>286.1</div>	<div>(iii) lysergic acid;</div>
<div>286.14</div>	<div>(iv) lysergic acid amide;</div>	<div>286.2</div>	<div>(iv) lysergic acid amide;</div>
<div>286.15</div>	<div>(v) methypylon;</div>	<div>286.3</div>	<div>(v) methypylon;</div>
<div>286.16</div>	<div>(vi) sulfondiethylmethane;</div>	<div>286.4</div>	<div>(vi) sulfondiethylmethane;</div>
<div>286.17</div>	<div>(vii) sulfonenthylmethane;</div>	<div>286.5</div>	<div>(vii) sulfonenthylmethane;</div>
<div>286.18</div>	<div>(viii) sulfonmethane;</div>	<div>286.6</div>	<div>(viii) sulfonmethane;</div>
<div>286.19</div>	<div>(ix) tiletamine and zolazepam and any salt thereof;</div>	<div>286.7</div>	<div>(ix) tiletamine and zolazepam and any salt thereof;</div>
<div>286.20</div>	<div>(x) embutramide;</div>	<div>286.8</div>	<div>(x) embutramide;</div>
<div>286.21</div> <div>286.22</div>	<div>(xi) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl)</div> <div>benzonitrile].</div>	<div>286.9</div> <div>286.10</div>	<div>(xi) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl)</div> <div>benzonitrile].</div>
<div>286.23</div>	<div>(d) Nalorphine.</div>	<div>286.11</div>	<div>(d) Nalorphine.</div>
<div>286.24</div> <div>286.25</div> <div>286.26</div> <div>286.27</div>	<div>(e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,</div> <div>any material, compound, mixture, or preparation containing any of the following narcotic</div> <div>drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities</div> <div>as follows:</div>	<div>286.12</div> <div>286.13</div> <div>286.14</div> <div>286.15</div>	<div>(e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,</div> <div>any material, compound, mixture, or preparation containing any of the following narcotic</div> <div>drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities</div> <div>as follows:</div>
<div>286.28</div> <div>286.29</div>	<div>(1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams</div> <div>per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;</div>	<div>286.16</div> <div>286.17</div>	<div>(1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams</div> <div>per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;</div>
<div>287.1</div> <div>287.2</div> <div>287.3</div>	<div>(2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams</div> <div>per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic</div> <div>amounts;</div>	<div>286.18</div> <div>286.19</div> <div>286.20</div>	<div>(2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams</div> <div>per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic</div> <div>amounts;</div>

287.4 (3) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90
 287.5 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
 287.6 therapeutic amounts;

287.7 (4) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than
 287.8 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
 287.9 therapeutic amounts;

287.10 (5) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
 287.11 more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
 287.12 in recognized therapeutic amounts;

287.13 (6) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
 287.14 one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

287.15 (f) Anabolic steroids, human growth hormone, and chorionic gonadotropin.

287.16 (1) Anabolic steroids, for purposes of this subdivision, means any drug or hormonal
 287.17 substance, chemically and pharmacologically related to testosterone, other than estrogens,
 287.18 progestins, corticosteroids, and dehydroepiandrosterone, and includes:

287.19 (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
 287.20 (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
 287.21 (iii) androstenedione (5[alpha]-androstan-3,17-dione);
 287.22 (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
 287.23 (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
 287.24 (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);
 287.25 (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);
 287.26 (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);
 287.27 (ix) 4-androstenedione (androst-4-en-3,17-dione);
 287.28 (x) 5-androstenedione (androst-5-en-3,17-dione);
 287.29 (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
 287.30 (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);
 288.1 (xiii) boldione (androsta-1,4-diene-3,17-dione);
 288.2 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
 288.3 (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);

286.21 (3) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90
 286.22 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
 286.23 therapeutic amounts;

286.24 (4) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than
 286.25 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
 286.26 therapeutic amounts;

286.27 (5) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
 286.28 more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
 286.29 in recognized therapeutic amounts;

286.30 (6) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
 286.31 one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

287.1 (f) Anabolic steroids, human growth hormone, and chorionic gonadotropin.

287.2 (1) Anabolic steroids, for purposes of this subdivision, means any drug or hormonal
 287.3 substance, chemically and pharmacologically related to testosterone, other than estrogens,
 287.4 progestins, corticosteroids, and dehydroepiandrosterone, and includes:

287.5 (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
 287.6 (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
 287.7 (iii) androstenedione (5[alpha]-androstan-3,17-dione);
 287.8 (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
 287.9 (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
 287.10 (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);
 287.11 (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);
 287.12 (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);
 287.13 (ix) 4-androstenedione (androst-4-en-3,17-dione);
 287.14 (x) 5-androstenedione (androst-5-en-3,17-dione);
 287.15 (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
 287.16 (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);
 287.17 (xiii) boldione (androsta-1,4-diene-3,17-dione);
 287.18 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
 287.19 (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);

House Language H0100-11		CANNABIS-ARTICLE 8		May 03, 2023 01:01 PM		Senate Language UEH0100-2	
288.4	(xvi) dehydrochloromethyltestosterone	287.20	(xvi) dehydrochloromethyltestosterone	288.1	(xxiii) formebolone	287.21	(xvi) dehydrochloromethyltestosterone
288.5	(4-chloro-17[beta]-hydroxy-17[alpha]-methylandro-1,4-dien-3-one);	287.21	(4-chloro-17[beta]-hydroxy-17[alpha]-methylandro-1,4-dien-3-one);	288.2	(2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandro-1,4-dien-3-one);	287.22	(4-chloro-17[beta]-hydroxy-17[alpha]-methylandro-1,4-dien-3-one);
288.6	(xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-andro-2-en-17[beta]-ol);	287.22	(xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-andro-2-en-17[beta]-ol);	288.3	(xxiv) furazabol	287.23	(xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-andro-2-en-17[beta]-ol);
288.7	(xviii) [delta]1-dihydrotestosterone- (17[beta]-hydroxy-5[alpha]-andro-1-en-3-one);	287.23	(xviii) [delta]1-dihydrotestosterone- (17[beta]-hydroxy-5[alpha]-andro-1-en-3-one);	288.4	(17[alpha]-methyl-17[beta]-hydroxyandro-2,3-c]-furazan)13[beta]-ethyl-17[beta]	287.24	(xviii) [delta]1-dihydrotestosterone- (17[beta]-hydroxy-5[alpha]-andro-1-en-3-one);
288.8	(xix) 4-dihydrotestosterone (17[beta]-hydroxy-andro-3-one);	287.24	(xix) 4-dihydrotestosterone (17[beta]-hydroxy-andro-3-one);	288.5	-hydroxygon-4-en-3-one;	287.25	(xix) 4-dihydrotestosterone (17[beta]-hydroxy-andro-3-one);
288.9	(xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-andro-3-one);	287.25	(xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-andro-3-one);	288.6	(xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandro-4-en-3-one);	287.26	(xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-andro-3-one);
288.10	(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);	287.26	(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);	288.7	(xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);	287.27	(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);
288.11	(xxii) fluoxymesterone	287.27	(xxii) fluoxymesterone	288.8	(xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-andro-3-one);	287.28	(xxii) fluoxymesterone
288.12	(9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandro-4-en-3-one);	287.28	(9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandro-4-en-3-one);	288.9	(xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-andro-3-one);	288.1	(xxiii) formebolone
288.13	(xxiii) formebolone	288.1	(xxiii) formebolone	288.10	(xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandro-1,4-dien-3-one);	288.2	(2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandro-1,4-dien-3-one);
288.14	(2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandro-1,4-dien-3-one);	288.2	(2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandro-1,4-dien-3-one);	288.11	(xxx) methandiol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandro-5-ene);	288.3	(xxiv) furazabol
288.15	(xxiv) furazabol	288.3	(xxiv) furazabol	288.12	(xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-andro-17beta-ol-3-one);	288.4	(17[alpha]-methyl-17[beta]-hydroxyandro-2,3-c]-furazan)13[beta]-ethyl-17[beta]
288.16	(17[alpha]-methyl-17[beta]-hydroxyandro-2,3-c]-furazan)13[beta]-ethyl-17[beta]	288.4	(17[alpha]-methyl-17[beta]-hydroxyandro-2,3-c]-furazan)13[beta]-ethyl-17[beta]	288.13	(xxxii) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-andro-1-en-3-one);	288.5	-hydroxygon-4-en-3-one;
288.17	-hydroxygon-4-en-3-one;	288.5	-hydroxygon-4-en-3-one;	288.14	(xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-andro-3-one);	288.6	(xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandro-4-en-3-one);
288.18	(xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandro-4-en-3-one);	288.6	(xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandro-4-en-3-one);	288.15	(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-andro-3-one);	288.7	(xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);
288.19	(xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);	288.7	(xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);	288.16	(xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandro-4-ene;	288.8	(xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-andro-3-one);
288.20	(xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-andro-3-one);	288.8	(xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-andro-3-one);	288.17	(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone	288.9	(xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-andro-3-one);
288.21	(xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-andro-3-one);	288.9	(xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-andro-3-one);	288.18	(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);	288.10	(xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandro-1,4-dien-3-one);
288.22	(xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandro-1,4-dien-3-one);	288.10	(xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandro-1,4-dien-3-one);	288.19	(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);	288.11	(xxx) methandiol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandro-5-ene);
288.23	(xxx) methandiol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandro-5-ene);	288.11	(xxx) methandiol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandro-5-ene);	288.20	(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);	288.12	(xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-andro-17beta-ol-3-one);
288.24	(xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-andro-17beta-ol-3-one);	288.12	(xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-andro-17beta-ol-3-one);	288.21	(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandro-4-en-3-one);	288.13	(xxxii) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-andro-1-en-3-one);
288.25	(xxxii) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-andro-1-en-3-one);	288.13	(xxxii) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-andro-1-en-3-one);			288.14	(xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-andro-3-one);
288.26	(xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-andro-3-one);	288.14	(xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-andro-3-one);			288.15	(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-andro-3-one);
288.27	(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-andro-3-one);	288.15	(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-andro-3-one);			288.16	(xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandro-4-ene;
288.28	(xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandro-4-ene;	288.16	(xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandro-4-ene;			288.17	(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone
289.1	(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone	288.17	(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone			288.18	(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
289.2	(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);	288.18	(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);			288.19	(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
289.3	(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);	288.19	(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);			288.20	(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);
289.4	(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);	288.20	(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);			288.21	(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandro-4-en-3-one);
289.5	(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandro-4-en-3-one);	288.21	(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandro-4-en-3-one);				

House Language H0100-11		CANNABIS-ARTICLE 8	May 03, 2023 01:01 PM	Senate Language UEH0100-2	
289.6	(xl) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);			288.22	(xl) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);
289.7	(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone			288.23	(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
289.8	(17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);			288.24	(17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);
289.9	(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one);			288.25	(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one);
289.10	(xliii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene;			288.26	(xliii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene;
289.11	(xliv) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol			288.27	(xliv) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol
289.12	(3[beta],17[beta]-dihydroxyestr-5-ene;			288.28	(3[beta],17[beta]-dihydroxyestr-5-ene;
289.13	(xlv) 3[alpha],17[beta]-dihydroxyestr-5-ene);			288.29	(xlv) 3[alpha],17[beta]-dihydroxyestr-5-ene);
289.14	(xlvi) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);			289.1	(xlvi) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
289.15	(xlvii) 19-nor-5-androstenedione (estr-5-en-3,17-dione);			289.2	(xlvii) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
289.16	(xlviii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);			289.3	(xlviii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);
289.17	(xlix) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);			289.4	(xlix) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
289.18	(l) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);			289.5	(l) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);
289.19	(li) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);			289.6	(li) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
289.20	(lii) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);			289.7	(lii) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);
289.21	(liii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);			289.8	(liii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);
289.22	(liv) oxymetholone			289.9	(liv) oxymetholone
289.23	(17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);			289.10	(17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);
289.24	(lv) prostanozol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pyrazole;			289.11	(lv) prostanozol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pyrazole;
289.25	(lvi) stanozolol			289.12	(lvi) stanozolol
289.26	(17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);			289.13	(17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);
289.27	(lvii) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);			289.14	(lvii) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);
289.28	(lviii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);			289.15	(lviii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
290.1	(lix) testosterone (17[beta]-hydroxyandrost-4-en-3-one);			289.16	(lix) testosterone (17[beta]-hydroxyandrost-4-en-3-one);
290.2	(lx) tetrahydrogestrinone			289.17	(lx) tetrahydrogestrinone
290.3	(13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);			289.18	(13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);
290.4	(lxi) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);			289.19	(lxi) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);
290.5	(lxii) any salt, ester, or ether of a drug or substance described in this paragraph.			289.20	(lxii) any salt, ester, or ether of a drug or substance described in this paragraph.

290.6 Anabolic steroids are not included if they are: (A) expressly intended for administration
 290.7 through implants to cattle or other nonhuman species; and (B) approved by the United States
 290.8 Food and Drug Administration for that use;

290.9 (2) Human growth hormones.

290.10 (3) Chorionic gonadotropin, except that a product containing chorionic gonadotropin is
 290.11 not included if it is:

290.12 (i) expressly intended for administration to cattle or other nonhuman species; and

290.13 (ii) approved by the United States Food and Drug Administration for that use.

290.14 (g) Hallucinogenic substances. Dronabinol (**synthetic**) in sesame oil and encapsulated
 290.15 in a soft gelatin capsule in a United States Food and Drug Administration approved product.

290.16 (h) Any material, compound, mixture, or preparation containing the following narcotic
 290.17 drug or its salt: buprenorphine.

290.18 (i) Marijuana, tetrahydrocannabinols, and **synthetic** cannabinoids. Unless specifically
 290.19 excepted or unless listed in another schedule, any natural or **synthetic** material, compound,
 290.20 mixture, or preparation that contains any quantity of the following substances, their analogs,
 290.21 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence
 290.22 of the isomers, esters, ethers, or salts is possible:

290.23 (1) marijuana;

290.24 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except
 290.25 that tetrahydrocannabinols do not include any material, compound, mixture, or preparation
 290.26 that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; **synthetic**
 290.27 equivalents of the substances contained in the cannabis plant or in the resinous extractives
 290.28 of the plant; or **synthetic** substances with similar chemical structure and pharmacological
 290.29 activity to those substances contained in the plant or resinous extract, including but not
 290.30 limited to 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4
 290.31 cis or trans tetrahydrocannabinol.

291.1 **EFFECTIVE DATE.** This section is effective the day following final enactment.

289.21 Anabolic steroids are not included if they are: (A) expressly intended for administration
 289.22 through implants to cattle or other nonhuman species; and (B) approved by the United States
 289.23 Food and Drug Administration for that use;

289.24 (2) Human growth hormones.

289.25 (3) Chorionic gonadotropin, except that a product containing chorionic gonadotropin is
 289.26 not included if it is:

289.27 (i) expressly intended for administration to cattle or other nonhuman species; and

289.28 (ii) approved by the United States Food and Drug Administration for that use.

290.1 (g) Hallucinogenic substances. Dronabinol (**synthetic artificial**) in sesame oil and
 290.2 encapsulated in a soft gelatin capsule in a United States Food and Drug Administration
 290.3 approved product.

290.4 (h) Any material, compound, mixture, or preparation containing the following narcotic
 290.5 drug or its salt: buprenorphine.

290.6 (i) Marijuana, tetrahydrocannabinols, and **artificial** cannabinoids. Unless specifically
 290.7 excepted or unless listed in another schedule, any natural or **artificial** material, compound,
 290.8 mixture, or preparation that contains any quantity of the following substances, their analogs,
 290.9 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence
 290.10 of the isomers, esters, ethers, or salts is possible:

290.11 (1) marijuana;

290.12 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except
 290.13 that tetrahydrocannabinols do not include any material, compound, mixture, or preparation
 290.14 that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; **artificial**
 290.15 equivalents of the substances contained in the cannabis plant or in the resinous extractives
 290.16 of the plant; or **artificial** substances with similar chemical structure and pharmacological
 290.17 activity to those substances contained in the plant or resinous extract, including but not
 290.18 limited to 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4
 290.19 cis or trans tetrahydrocannabinol.

290.20 **EFFECTIVE DATE.** This section is effective the day following final enactment.